Intellia Therapeutics (NTLA) is back in focus after reporting strong Phase 3 data for lonvoguran ziclumeran in hereditary angioedema, outlining regulatory submission plans, and pairing the update with an upsized equity raise.

Despite a modest 1-day share price decline of 0.37% to US$13.49 and a softer 30-day share price return of 4.26% down, the year-to-date share price return of 46.47% and 1-year total shareholder return of 62.92% suggest momentum has picked up after earlier multi year total shareholder return declines.

If Intellia’s update has you thinking more broadly about genomic medicine and AI driven drug development, it could be worth scanning 39 healthcare AI stocks

So with Intellia’s share price still far below some analyst targets, yet backed by fresh Phase 3 data, cash through at least 2028 and rising attention on CRISPR, is the stock mispriced or already reflecting future growth?

Most Popular Narrative: 49.3% Undervalued

Analysts following Intellia see a fair value of $26.63 per share, compared with the last close at $13.49, and anchor that view on aggressive growth and profitability assumptions filtered through a 7.14% discount rate.

The analysts have a consensus price target of $26.63 for Intellia Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.

In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $847.4 million, earnings will come to $46.7 million, and it would be trading on a PE ratio of 120.0x, assuming you use a discount rate of 7.1%.

Want to see what justifies nearly doubling the current share price in this narrative? The crux is a sharp swing from sizeable losses to positive earnings, paired with rapid revenue expansion and a rich future earnings multiple more often associated with established growth stars. Curious which specific growth and margin paths are baked into that view, and how they balance against execution risk and dilution assumptions? The full narrative lays those building blocks out in detail.

Result: Fair Value of $26.63 (UNDERVALUED)

However, this upside story can crack if late stage trials stumble or if high development costs and equity raises weigh more heavily on future shareholder returns.

Another View: Rich Multiples Versus Fair Value Signal

Analysts’ fair value of $26.63 paints Intellia as 49.3% undervalued, yet the current P/S of 28.5x looks expensive compared with both the US Biotechs industry at 10.5x and a fair ratio of 0.1x. That gap points to meaningful valuation risk, so which signal do you trust?

Next Steps

If this mix of optimism and concern feels familiar, act while the information is fresh and take time to weigh both sides for yourself with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

Do not stop at one stock story. Broaden your watchlist with clear themes so you are not relying on a single outcome or sector.

Use the Simply Wall Street Screener to uncover fresh opportunities that match how you like to invest, before the crowd shifts attention and prices move away from you.

• Target possible higher upside potential by reviewing 23 elite penny stocks with strong financials that pair smaller market caps with more robust financial profiles than many peers.
• Refine your hunt for value by filtering through the 47 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet.
• Prioritise resilience and support more peace of mind by focusing on 63 resilient stocks with low risk scores that score well on financial health and lower risk indicators.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.